GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (NAS:ACCD) » Definitions » Sloan Ratio %

Accolade (Accolade) Sloan Ratio % : -10.86% (As of Nov. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Accolade Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Accolade's Sloan Ratio for the quarter that ended in Nov. 2023 was -10.86%.

Warning Sign:

When sloan ratio (-45.59)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Nov. 2023, Accolade has a Sloan Ratio of -10.86%, indicating earnings are more likely to be made up of accruals.


Accolade Sloan Ratio % Historical Data

The historical data trend for Accolade's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accolade Sloan Ratio % Chart

Accolade Annual Data
Trend Feb18 Feb19 Feb20 Feb21 Feb22 Feb23
Sloan Ratio %
Get a 7-Day Free Trial -56.00 -18.56 -4.84 15.78 -45.59

Accolade Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.74 -45.59 -13.29 -11.23 -10.86

Competitive Comparison of Accolade's Sloan Ratio %

For the Health Information Services subindustry, Accolade's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accolade's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Accolade's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Accolade's Sloan Ratio % falls into.



Accolade Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Accolade's Sloan Ratio for the fiscal year that ended in Feb. 2023 is calculated as

Sloan Ratio=(Net Income (A: Feb. 2023 )-Cash Flow from Operations (A: Feb. 2023 )
-Cash Flow from Investing (A: Feb. 2023 ))/Total Assets (A: Feb. 2023 )
=(-459.65--40.705
--7.228)/903.069
=-45.59%

Accolade's Sloan Ratio for the quarter that ended in Nov. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Nov. 2023 )
=(-122.731--24.679
--12.788)/785.471
=-10.86%

Accolade's Net Income for the trailing twelve months (TTM) ended in Nov. 2023 was -30.433 (Feb. 2023 ) + -38.409 (May. 2023 ) + -32.825 (Aug. 2023 ) + -21.064 (Nov. 2023 ) = $-122.7 Mil.
Accolade's Cash Flow from Operations for the trailing twelve months (TTM) ended in Nov. 2023 was -2.559 (Feb. 2023 ) + -19.287 (May. 2023 ) + -8.038 (Aug. 2023 ) + 5.205 (Nov. 2023 ) = $-24.7 Mil.
Accolade's Cash Flow from Investing for the trailing twelve months (TTM) ended in Nov. 2023 was -2.413 (Feb. 2023 ) + -3.377 (May. 2023 ) + -3.286 (Aug. 2023 ) + -3.712 (Nov. 2023 ) = $-12.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accolade  (NAS:ACCD) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Nov. 2023, Accolade has a Sloan Ratio of -10.86%, indicating earnings are more likely to be made up of accruals.


Accolade Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Accolade's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Accolade (Accolade) Business Description

Traded in Other Exchanges
Address
1201 Third Avenue, Suite 1700, Seattle, WA, USA, 98101
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. It generates revenue by providing personalized health guidance solutions to members.
Executives
Richard Eskew officer: EVP General Counsel C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Stephen H. Barnes officer: Chief Financial Officer C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Rajeev Singh director, officer: Chief Executive Officer 6222 185TH AVENUE NE, REDMOND WA 98052
Robert N Cavanaugh officer: President 1601 CLOVERFIELD BLVD., SUITE 620, SANTA MONICA CA 90404
Mchugh Colin officer: Chief Accounting Officer C/O ACCOLADE, INC., 660 W. GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Michael W Hilton officer: Chief Product Officer 6222 185TH AVE, REDMOND WA 98052
Peter S Klein director C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY, REDMOND WA 98052-6399
Cindy Kent director 7601 PENN AVENUE SOUTH, RICHFIELD MN 55418
Patricia L Wadors director C/O ALIGN TECHNOLOGY INC, 881 MARTIN AVE, SANTA CLARA CA 95050
Dawn G Lepore director 1425 BROADWAY PMB 41, SEATTLE WA 99122
Jeffrey D Jordan director 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
Jeffrey S Brodsky director C/O MORGAN STANLEY 1585 BROADWAY, NEW YORK NY 10036
Thomas J Neff director SPENCER STUART & ASSOCIATES, 277 PARK AVE, NEW YORK NY 10172
William H. Frist director 600 MONTGOMERY STREET, SAN FRANCISCO CA 94111

Accolade (Accolade) Headlines